Skip to content
Mesa Joint Care Guide
Joint-care language, decoded in the East Valley

Mesa Joint Care Guide

Common questions about sore joints and treatment

What do people usually ask about a sore joint? They want to know why it aches, what may help now, and what each treatment can and can’t do. The answers below are brief and direct.

We’ll stay with useful questions.

What is regenerative medicine?

It means clinic care that uses material from a body. PRP is one example because it begins with your blood. The name can’t promise relief. You’re welcome to ask what will be used and who will provide the care.

Why does sitting make my joint ache?

Rest may leave a worn or irritated joint feeling stiff. The first steps may hurt, then movement may loosen it. Easy bends and warmth may help. An exam is worthwhile if the ache keeps worsening or wakes you.

How can I calm joint soreness at home?

You might shorten the activity that stirred up the ache without stopping all movement. Try a brief walk, or ease the joint through a bend and back again. Warmth may loosen stiffness, while cooling after activity may settle soreness. Your doctor or pharmacist can check pain medicine against your other medicines.

When does a sore joint need urgent care?

Please seek quick care if the joint becomes hot, very swollen, and painful while you have a fever, or if a fall leaves you unable to stand or with a joint that looks out of place. Sudden bowel or bladder trouble, weakness, or numbness can be an emergency.

Does regenerative medicine work?

Some people report less soreness or easier movement, while others feel little change. Results differ by treatment and by person. Research hasn’t shown steady rebuilding of worn cartilage. After an exam, a doctor or licensed health professional can discuss realistic relief with you.

What is PRP?

PRP is an abbreviation for platelet-rich plasma. The clinic puts your blood in a machine that separates its parts, leaving plasma with more platelets. The small blood parts that help a clot form are called platelets. Concentrated PRP has a greater amount of platelets in the blood mixture used for care.

What is a joint visit like?

A doctor or licensed health professional will ask where it hurts and which movements are hard. The exam checks swelling, tender spots, movement, and strength. A scan may follow. Then you can discuss the likely cause, choices, cost, and recovery.

How much is PRP for a knee in Mesa or Gilbert?

Cost can differ with the blood mixture used and the care included. We don’t have a dependable local price to give you. The clinic can put each charge in writing, including the visit, treatment, and later checks. Then you can compare the full cost with the relief you may expect.

Sources

  1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

    Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

  2. A Nature comment by Sipp, Robey and Turner arguing that loose use of 'mesenchymal stem cell' across an enormous range of unrelated cell preparations has produced a scientific and commercial mess, and calling for the terminology and the evidentiary standards to be tightened. Included because the objection to the word comes from inside stem cell science, not from its critics.

    Sipp D, et al. — Clear up this stem-cell mess.. Nature, 2018. DOI: 10.1038/d41586-018-06756-9.

  3. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations.

    Zhang EJX, et al. — Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.. Orthopaedic journal of sports medicine, 2026. DOI: 10.1177/23259671261443876.

  4. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX at Level III evidence or higher (4 Level II, 2 Level III), covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment - meaning no consensus exists on indications, cell sources, preparation or delivery. Two products called 'stem cell therapy' at two clinics may share almost nothing.

    Chahla J, et al. — Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.. The Journal of bone and joint surgery. American volume, 2016. DOI: 10.2106/JBJS.15.01495.

  5. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected.

    Nakagawa HF, et al. — Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.. The American journal of sports medicine, 2025. DOI: 10.1177/03635465241249996.

  6. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

    US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

  7. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA and strongly recommends topical NSAIDs (Level 1A), while strongly recommending AGAINST oral and transdermal opioids (Level 5). The treatments with the strongest evidence in this condition remain the least dramatic ones.

    Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

There’s time to talk through your sore joint

If you’d like to discuss the soreness, the first consultation costs you nothing. You can bring your medicines, scan notes, and the name of earlier care. It may also help to note the activity you miss most. The clinic team answers at (602) 837-PAIN.

Book a free consultation